Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Boehringer Ingelheim
Express Scripts
McKesson
Baxter

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR AUBAGIO


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Aubagio

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00622700 ↗ Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis Completed Sanofi Phase 3 2008-02-01 The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS). The secondary objectives were: - To demonstrate the effect of teriflunomide, in comparison to placebo, on: - Reducing conversion to definite multiple sclerosis (DMS) - Reducing annualized relapse rate (ARR) - Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI) - Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS) - Proportion of disability-free participants as assessed by the EDSS - Reducing participant-reported fatigue - To evaluate the safety and tolerability of teriflunomide - To evaluate the pharmacokinetics (PK) of teriflunomide - Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes
NCT00803049 ↗ Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis Completed Sanofi Phase 3 2006-10-01 The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse. The secondary objective was to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.
NCT01466114 ↗ Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting Synthetic Biologics (formerly Adeona Pharmaceuticals) Phase 2 2011-10-01 Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT01466114 ↗ Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Recruiting University of California, Los Angeles Phase 2 2011-10-01 Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with cognition. Currently, there are no FDA-approved treatments targeting cognitive function in Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as compared to treatment with a placebo pill in combination with standard anti-inflammatory drugs in women with MS.
NCT01970410 ↗ Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV Recruiting Multiple Sclerosis Center of Northeastern New York Phase 4 2013-10-01 The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for PML. This is a two center interventional study of patients who have had 12 or more continuous infusions of natalizumab , who are anti-JCV-ab positive, and who had been free of clinical relapses during prior 12 months of natalizumab therapy who will be switching to teriflunomide.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aubagio

Condition Name

Condition Name for Aubagio
Intervention Trials
Relapsing Multiple Sclerosis 5
Multiple Sclerosis 3
Healthy Volunteers 1
Primary-progressive Multiple Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aubagio
Intervention Trials
Multiple Sclerosis 11
Sclerosis 10
Multiple Sclerosis, Relapsing-Remitting 3
Leukoencephalopathy, Progressive Multifocal 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aubagio

Trials by Country

Trials by Country for Aubagio
Location Trials
United States 154
Spain 23
India 14
Canada 13
Italy 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aubagio
Location Trials
Florida 9
Michigan 8
Pennsylvania 7
Ohio 7
Indiana 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aubagio

Clinical Trial Phase

Clinical Trial Phase for Aubagio
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aubagio
Clinical Trial Phase Trials
Completed 5
Recruiting 4
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aubagio

Sponsor Name

Sponsor Name for Aubagio
Sponsor Trials
Sanofi 4
Novartis Pharmaceuticals 2
EMD Serono Research & Development Institute, Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aubagio
Sponsor Trials
Industry 12
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Merck
Moodys
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.